Who are Complement Therapeutics's investors?

Complement Therapeutics's investors include BioGeneration Ventures, Cambridge Innovation Capital, Gimv, Hadean Ventures, Seroba Life Sciences, BGV, Forbion, Novo Holdings and 1 more.

Where is Complement Therapeutics headquartered?

Complement Therapeutics is headquartered in Munich, DE.

Complement Therapeutics

Munich, DE · 11 known investors

Find your way into Complement Therapeutics

Paths you didn't know you had: your email and LinkedIn already hold routes to the Complement Therapeutics team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Complement Therapeutics is a clinical-stage biotechnology company developing gene therapies for complement-mediated diseases, with a lead AAV-based candidate (CTx001) for Geographic Atrophy secondary to Age-related Macular Degeneration. A University of Manchester spinout, it runs clinical and natural history studies in ophthalmology across the US and UK.

Biotech Digital Health Healthtech Medical Devices

Founders & leadership

Rafiq Hasan CEO and Managing DirectorSenior Advisor at BioGeneration Ventures

Muhammad Ali Memon Chief Medical OfficerMuhammad Ali Memon is a UK-trained ophthalmologist with clinical and research expertise in retinal diseases, previously serving as a consultant at King's College London and honorary consultant at Moorfields Eye Hospital. His background includes experience with clinical trials across multiple phases and research positions at Harvard University and Imperial College London.

Investors · 11

BioGeneration Ventureslisted by BioGeneration VenturesNaarden

How we know: BioGeneration Ventures's portfolio page · funding news · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us

Cambridge Innovation Capitallisted by Cambridge Innovation CapitalCambridge · $127K – $12.7M

How we know: Cambridge Innovation Capital's portfolio page · a partner's Signal profile · hadeanventures.com · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us

Gimvlisted by GimvAntwerp · $20M – $400M

How we know: Gimv's portfolio page · funding news · hadeanventures.com · open dataset · 5k.vc investor directory · Not right? Tell us

Hadean Ventureslisted by Hadean VenturesOslo

How we know: Hadean Ventures's portfolio page · funding news · hadeanventures.com · open dataset · 5k.vc investor directory · Not right? Tell us

Seroba Life Scienceslisted by Seroba Life SciencesDublin · $540K – $7.6M

How we know: Seroba Life Sciences's portfolio page · hadeanventures.com · Not right? Tell us

BGVreportedSilicon Valley

How we know: funding news · press coverage · Not right? Tell us

ForbionreportedNaarden

How we know: a partner's Signal profile · funding news · hadeanventures.com · open dataset · 5k.vc investor directory · Not right? Tell us

Novo HoldingsreportedCopenhagen · $1.1M – $54M

How we know: a partner's Signal profile · Not right? Tell us

Panakes PartnersreportedMilan

How we know: labiotech.eu · open dataset · 5k.vc investor directory · Not right? Tell us

Also in the syndicate · 2

BioGeneration Ventures (BGV)Panakès Partners

Funding

SEC filings, press & company announcements

Undisclosed amountSeries AApr 2023 · 2 sources
Gimv (lead), BioGeneration Ventures (BGV), Cambridge Innovation Capital (CIC), Forbion, Hadean Ventures, Panakes Partners, Panakès Partners, Seroba Life Sciences
Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

Founder mafia

2 people who came through Complement Therapeutics went on to found or lead other companies.

John FordChairmanFounded Metrion Biosciences +1 Steven AxonBoard MemberFounded Glycomine

Related companies · 3

Inmune BioINmune Bio is a clinical-stage biotechnology company developing immunotherapies, including XPro1595, aimed at treating neurodegenerative and psychiatric diseases through a biomarker-directed approach. The company works on translating inflammatory therapies into clinical treatments for neurologic and other diseases.

Cellular OriginsCellular Origins provides automated cell therapy manufacturing solutions through its Constellation platform, which integrates robotics and digital management to enable GMP-compliant scaling of cell therapies with minimal process modification.

Resolution TherapeuticsResolution develops a macrophage cell therapy to treat end-stage liver disease, aiming to reduce the need for liver transplantation and improve patient outcomes. The company focuses on regenerative medicine for inflammatory and fibrotic diseases.

Companies working in the same space as Complement Therapeutics.

Frequently asked questions

What does Complement Therapeutics do?: Complement Therapeutics is a clinical-stage biotechnology company developing gene therapies for complement-mediated diseases, with a lead AAV-based candidate (CTx001) for Geographic Atrophy secondary to Age-related Macular Degeneration. A University of Manchester spinout, it runs clinical and natural history studies in ophthalmology across the US and UK.
Who are Complement Therapeutics's investors?: Complement Therapeutics's investors include BioGeneration Ventures, Cambridge Innovation Capital, Gimv, Hadean Ventures, Seroba Life Sciences, BGV, Forbion, Novo Holdings and 1 more.
Where is Complement Therapeutics headquartered?: Complement Therapeutics is headquartered in Munich, DE.